Please Wait.....
Report
Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and Others), Disease Cause (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity), Sales Channel (Hospital Pharmacy, Online Providers, Retail Pharmacy), End User (Hospitals, Clinics, Homecare Settings), and Region 2025-2033
Market Report I 2025-03-01 I 142 Pages I IMARC Group
The global non-alcoholic steatohepatitis (NASH) market size reached USD 1.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 13.5 Billion by 2033, exhibiting a growth rate (CAGR) of 22.97% during 2025-2033. The rising prevalence of NASH, increasing awareness regarding early diagnosis and treatments, and the integration of artificial intelligence (AI) and machine learning (ML) technologies represent some of the key factors driving the market.
Non-alcoholic steatohepatitis (NASH) refers to a progressive non-alcoholic fatty liver disease (NAFLD) caused by insulin resistance, overweight, and metabolic syndrome. Its symptoms involve fatigue and weakness, weight loss, jaundice, itchy skin, spider veins, enlarged liver, lack of concentration, fluid accumulation, and abdominal discomfort, such as pain and swelling. It is diagnosed through multiple techniques, such as physical examination, blood test, liver biopsy, magnetic resonance imaging (MRI), ultrasound, and computed tomography (CT) scan. NASH treatment includes medication, liver transplant, and various lifestyle modifications, such as regular exercise, and healthy diets. These treatment methods aid in reducing liver fat accumulation, improving liver function, reducing inflammation, and minimizing liver damage. They also enhance patients' quality of life, improve long-term outcomes, and allow better management of other health problems, such as obesity and high blood pressure.
Non-Alcoholic Steatohepatitis (NASH) Market Trends:
The rising prevalence of NASH due to genetics, sedentary lifestyle, unhealthy eating habits, obesity, and type 2 diabetes is one of the key factors driving the market growth. In line with this, NASH treatments are widely adopted by patients to alleviate symptoms, increase lifespan, prevent premature death, improve liver health, and promote overall well-being, which in turn is providing a thrust to the market growth. Furthermore, the increasing awareness among the masses regarding early diagnosis and treatment of NASH to reduce healthcare expenses, eliminate the need for liver transplants, and prevent future complications, such as high blood pressure, cardiovascular diseases (CVDs), cancer, cirrhosis, and liver failure is providing an impetus to the market growth. Additionally, the utilization of non-invasive imaging techniques to monitor and diagnose NASH, such as MRI and transient elastography (TE), which, in turn, enhances patients' comfort, increases compliance, reduces the risk of complications, and improves clinical outcomes, is positively influencing the market growth. Besides this, the integration of artificial intelligence (AI) and machine learning (ML) to develop personalized treatments, improve diagnosis accuracy, and predict disease progression is favoring the market growth. Moreover, the implementation of various government initiatives to provide access to high-quality treatment and support the development of advanced therapeutics is propelling the market growth. Other factors, including the rising geriatric population, increasing healthcare expenditure, extensive research and development (R&D) activities, significant growth in the healthcare industry, and the increasing demand for non-invasive treatment options, are anticipated to drive the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global non-alcoholic steatohepatitis (NASH) market, along with forecasts at the global, regional, and country levels from 2025-2033. Our report has categorized the market based on drug type, disease cause, sales channel, and end user.
Drug Type Insights:
- Vitamin E and Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cenicriviroc
- Others
The report has provided a detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the drug type. This includes Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and others. According to the report, vitamin E and pioglitazone represented the largest segment.
Disease Cause Insights:
- Hypertension
- Heart Disease
- High Blood Lipid
- Type 2 Diabetes
- Obesity
A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the disease cause has also been provided in the report. This includes hypertension, heart disease, high blood lipid, type 2 diabetes, and obesity. According to the report, obesity accounted for the largest market share.
Sales Channel Insights:
- Hospital Pharmacy
- Online Providers
- Retail Pharmacy
A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the sales channel has also been provided in the report. This includes hospital pharmacy, online providers, and retail pharmacy. According to the report, retail pharmacy accounted for the largest market share.
End User Insights:
- Hospitals
- Clinics
- Homecare Settings
A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the end user has also been provided in the report. This includes hospitals, clinics, and homecare settings. According to the report, clinics accounted for the largest market share.
Regional Insights:
- North America
- United States
- Canada
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for non-alcoholic steatohepatitis (NASH). Some of the factors driving the North America non-alcoholic steatohepatitis (NASH) market included the rising prevalence of NASH, increasing government initiatives, and rapid technological advancements.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global non-alcoholic steatohepatitis (NASH) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Algernon Pharmaceuticals, Galmed Pharmaceuticals Ltd, Intercept Pharmaceuticals Inc., Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report
1.How big is the global Non-Alcoholic Steatohepatitis (NASH) market?
2.What is the expected growth rate of the global Non-Alcoholic Steatohepatitis (NASH) market during 2025-2033?
3.What are the key factors driving the global Non-Alcoholic Steatohepatitis (NASH) market?
4.What has been the impact of COVID-19 on the global Non-Alcoholic Steatohepatitis (NASH) market?
5.What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the drug type?
6.What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the disease cause?
7.What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the sales channel?
8.What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the end user?
9.What are the key regions in the global Non-Alcoholic Steatohepatitis (NASH) market?
10.Who are the key players/companies in the global Non-Alcoholic Steatohepatitis (NASH) market?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Non-Alcoholic Steatohepatitis (NASH) Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Type
6.1 Vitamin E and Pioglitazone
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Ocaliva
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Elafibranor
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Selonsertib
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Cenicriviroc
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 Market Breakup by Disease Cause
7.1 Hypertension
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Heart Disease
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 High Blood Lipid
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Type 2 Diabetes
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Obesity
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by Sales Channel
8.1 Hospital Pharmacy
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Online Providers
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Retail Pharmacy
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by End User
9.1 Hospitals
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Clinics
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Homecare Settings
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 Drivers, Restraints, and Opportunities
11.1 Overview
11.2 Drivers
11.3 Restraints
11.4 Opportunities
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Algernon Pharmaceuticals
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.2 Galmed Pharmaceuticals Ltd
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.3 Intercept Pharmaceuticals Inc.
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 Zydus Lifesciences Limited
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Figure 1: Global: Non-Alcoholic Steatohepatitis Market: Major Drivers and Challenges
Figure 2: Global: Non-Alcoholic Steatohepatitis Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 4: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Drug Type (in %), 2024
Figure 5: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Disease Cause (in %), 2024
Figure 6: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Sales Channel (in %), 2024
Figure 7: Global: Non-Alcoholic Steatohepatitis Market: Breakup by End User (in %), 2024
Figure 8: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Region (in %), 2024
Figure 9: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market: Sales Value (in Million USD), 2019 & 2024
Figure 10: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 11: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market: Sales Value (in Million USD), 2019 & 2024
Figure 12: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 13: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market: Sales Value (in Million USD), 2019 & 2024
Figure 14: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 15: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market: Sales Value (in Million USD), 2019 & 2024
Figure 16: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 17: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market: Sales Value (in Million USD), 2019 & 2024
Figure 18: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 19: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
Figure 20: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 21: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market: Sales Value (in Million USD), 2019 & 2024
Figure 22: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 23: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market: Sales Value (in Million USD), 2019 & 2024
Figure 24: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 25: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market: Sales Value (in Million USD), 2019 & 2024
Figure 26: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 27: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market: Sales Value (in Million USD), 2019 & 2024
Figure 28: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 29: Global: Non-Alcoholic Steatohepatitis (Obesity) Market: Sales Value (in Million USD), 2019 & 2024
Figure 30: Global: Non-Alcoholic Steatohepatitis (Obesity) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 31: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
Figure 32: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 33: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market: Sales Value (in Million USD), 2019 & 2024
Figure 34: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 35: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
Figure 36: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 37: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
Figure 38: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 39: Global: Non-Alcoholic Steatohepatitis (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 40: Global: Non-Alcoholic Steatohepatitis (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 41: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market: Sales Value (in Million USD), 2019 & 2024
Figure 42: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 43: North America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 44: North America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 45: United States: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 46: United States: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 47: Canada: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 48: Canada: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 49: Asia-Pacific: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 50: Asia-Pacific: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 51: China: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 52: China: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 53: Japan: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 54: Japan: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 55: India: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 56: India: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 57: South Korea: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 58: South Korea: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 59: Australia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 60: Australia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 61: Indonesia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 62: Indonesia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 63: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 64: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 65: Europe: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 66: Europe: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 67: Germany: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 68: Germany: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 69: France: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 70: France: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 71: United Kingdom: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 72: United Kingdom: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 73: Italy: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 74: Italy: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 75: Spain: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 76: Spain: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 77: Russia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 78: Russia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 79: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 80: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 81: Latin America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 82: Latin America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 83: Brazil: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 84: Brazil: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 85: Mexico: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 86: Mexico: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 87: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 88: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 89: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 90: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Breakup by Country (in %), 2024
Figure 91: Middle East and Africa: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 92: Global: Non-Alcoholic Steatohepatitis Industry: Drivers, Restraints, and Opportunities
Figure 93: Global: Non-Alcoholic Steatohepatitis Industry: Value Chain Analysis
Figure 94: Global: Non-Alcoholic Steatohepatitis Industry: Porter's Five Forces Analysis
Table 1: Global: Non-Alcoholic Steatohepatitis Market: Key Industry Highlights, 2024 & 2033
Table 2: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
Table 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Disease Cause (in Million USD), 2025-2033
Table 4: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Sales Channel (in Million USD), 2025-2033
Table 5: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by End User (in Million USD), 2025-2033
Table 6: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 7: Global: Non-Alcoholic Steatohepatitis Market: Competitive Structure
Table 8: Global: Non-Alcoholic Steatohepatitis Market: Key Players
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security